Autopsy report · NCT02113267

Mometasone-furoate for Treatment of Eosinophilic Esophagitis - a Randomized Placebo Controlled Study.

“Combination slow recruitment, short shelf life for placebo and insufficient funding for further drug production (probably anyway sufficient number included).”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 4 years 5 months before it stopped.
• 40 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Mogens Bove

Sponsor type

Government (non-US federal)

Conditions

Eosinophilic Esophagitis

Interventions

Mometasone furoate; Placebo

Participants

40

Sites

1

Countries

Sweden

Trials that died the same way

• TPF Followed by Cetuximab and IMRT Plus Carbon Ion Boost for Locally Advanced Head and Neck Tumors
  “slow recruitment (only 8 patients recruited and treated until 12/2012)” (66% match in meaning)
• rhEndostatin Protein Involving Pediatric Patients With Cancer
  “Lack of drug supply” (65% match in meaning)
• Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy
  “Slow accrual; drug availability” (64% match in meaning)
• Bevacizumab vs Dacarbazine in Metastatic Melanoma
  “Lack of financing of the study drug. Not sufficient financial support.” (63% match in meaning)
• Effects of Antrodia Cinnamomea on the Hepatoma Patients After Transcatheter Hepatic Artery Chemoembolization
  “poor accrual and insufficient drug supply” (61% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.